RecruitingNCT07216521
Intent of Surgery for IPMN
Studying Intraductal papillary mucinous carcinoma of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NYU Langone Health
- Principal Investigator
- Greg Sacks, MD MPH PhDNYU Langone Health
- Enrollment
- 2000 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2025
Study locations (14)
- Mayo Clinic, Phoenix, Arizona, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- NYU Langone Health, New York, New York, United States
- Memorial Sloan Kettering, New York, New York, United States
- Duke University, Durham, North Carolina, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Nanjing University, Nanjing, China
- Heidelberg University, Heidelberg, Germany
- San Raffaele Hospital, Milan, Italy
- Padua University, Padua, Italy
- University of Amsterdam, Amsterdam, Netherlands
- University of Utrecht, Utrecht, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07216521 on ClinicalTrials.govOther trials for Intraductal papillary mucinous carcinoma of pancreas
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07117045Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic CancerChanghai Hospital
- RECRUITINGNCT06574373Identification of New Theranostic Biomarkers of Pancreatic Tumor ProgressionFondazione Policlinico Universitario Agostino Gemelli IRCCS
- ACTIVE NOT RECRUITINGNANCT06712797Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception CenterH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06694792Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) ConsortiumIRCCS San Raffaele
- ENROLLING BY INVITATIONNCT06276764The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)Adenocyte, LLC
- RECRUITINGNCT06638866AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening CohortChanghai Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT06519097Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)H. Lee Moffitt Cancer Center and Research Institute
- ENROLLING BY INVITATIONNCT06283576Pancreatic Cancer Initial Detection Via Liquid BiopsyKarolinska University Hospital
See all trials for Intraductal papillary mucinous carcinoma of pancreas →